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Summary
Objective: The aim of this study was to examine the effects of recombinant human Fgf18 on chondrocyte proliferation and matrix production
in vivo and in vitro. In addition, the expressions of Fgf18 and Fgf receptors (Fgfr) in adult human articular cartilage were examined.
Methods: Adenovirus-mediated transfer of Fgf18 into murine pinnae and addition of FGF18 to primary cultures of adult articular chondrocytes
were used to assess the effects of FGF18 on chondrocytes. In situ hybridization was used to examine the expression of Fgf18 and Fgfrs in
adult human articular cartilage.
Results: Expression of Fgf18 by adenovirus-mediated gene transfer in murine pinnae resulted in a significant increase in chondrocyte
number. Chondrocytes were identified by staining with toluidine blue and a monoclonal antibody directed against type II collagen. Fgf18, Fgfr
2-(IIIc), Fgfr 3-(IIIc), and Fgfr 4 mRNAs were detected within these cells by in situ hybridization. The nuclei of the chondrocytes stained with
antibodies to PCNA and FGF receptor (FGFR) 2. Addition of FGF18 to the culture media of primary articular chondrocytes increased the
proliferation of these cells and increased their production of extracellular matrix. To assess the receptor selectivity of FGF18, BaF3 cells
stably expressing the genes for the major splice variants of Fgfr 1–3 were used. Proliferation of cells expressing Fgfr 3-(IIIc) or Fgfr 2-(IIIc)
was increased by incubation with FGF18. Using FGFR–Fc fusion proteins and BaF3 cells expressing Fgfr 3-(IIIc), only FGFR 3-(IIIc)-Fc,
FGFR 2-(IIIc)-Fc or FGFR 4-Fc reduced FGF18-mediated cell proliferation. Expression of Fgf18, Fgfr 3-(IIIc) and Fgfr 2-(IIIc) mRNAs was
localized to chondrocytes of human articular cartilage by in situ hybridization.
Conclusion: These data demonstrate that Fgf18 can act as a trophic factor for elastic chondrocytes and their progenitors in vivo and articular
chondrocytes cultured in vitro. Expression of Fgf18 and the genes for two of its receptors in chondrocytes suggests that Fgf18 may play an
autocrine role in the biology of normal articular cartilage. © 2002 OsteoArthritis Research Society International
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Cartilages are specialized connective tissues that dissipate
loads as the bearing surfaces in joints (hyaline cartilages
and fibrocartilages), interface between tendons, ligaments,
and bone (fibrocartilage), and provide a flexible support
for soft tissues (elastic cartilages, e.g. pinna, and hyaline
cartilages, e.g. trachea). All cartilage subtypes are com-
posed of chondrocytes embedded in a complex extra-
cellular matrix containing collagens, proteoglycans, and
non-collagenous proteins. The amount of extracellular
matrix and its composition most obviously differentiate
between cartilage types. For example, hyaline and elastic
cartilages contain predominately type II collagen, whereas
fibrocartilages contain predominately type I collagen1,2.
Trauma and disease of the synovial joint frequently
cause structural damage to the articular cartilage. Changes
include age-related fibrillation, cartilage degeneration due
to osteoarthritis (OA), and focal chondral and osteochon-308dral defects2. In most other tissues, such lesions would be
rapidly repaired. Adult articular cartilage, however, has
only a very limited capacity to heal2. Efforts to stimulate
cartilage healing have focussed on two general areas:
surgical procedures2, designed to stimulate the endogen-
ous repair response, and biological repair, designed to
stimulate chondrocyte proliferation and/or matrix produc-
tion by the application of peptide growth factors 3 or by cell
transplantation4.
As part of a bioinformatics-driven search for novel genes
with potential clinical utility, a novel member of the fibro-
blast growth factor (FGF) family of genes was identified5.
This gene and its encoded protein were subsequently given
the designation of Fgf18 by the Human Genome Organiz-
ation. It has been mapped to chromosome 5q345 and is a
member of Fgf8 and Fgf17 subfamily of FGFs6. As part of a
screen for factors that regulate angiogenesis, Fgf18 was
expressed by adenovirus-mediated gene transfer in the
pinnae of nude mice. Although an angiogenic response
was not observed, a surprising phenotype developed: com-
pared to pinnae that received null adenovirus, those that
received adenovirus-expressing Fgf18 became visibly
thicker. The increase in thickness was largely due to an
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FGF-MEDIATED PROLIFERATION OF FGFR-BAF3 CELLS
Cultures were maintained in growth media containing
RPMI 1640 media (Life Technologies, Rockville, MD,
U.S.A.) containing 10% fetal bovine serum (FBS),
L-glutamine, 600 g G418/ml, and 2.0 ng/ml murine IL-3
(R&D Systems, Minneapolis, MN, U.S.A.) in a 37°C humidi-
fied atmosphere of 95% air and 5% CO2. For mitogenic
assays, cells were washed three times with assay media
containing RPMI 1640, 10% FBS, L-glutamine, 600 g
G418/ml, 2.0 g/ml porcine intestinal heparin (Sigma
Chemical Company (St Louis, MO, U.S.A.) and no IL-3.
Cells were plated at 10,000 cells per well in 96-well
microtiter plates in 200 l of assay medium containing
various concentrations of growth factors. In some exper-
iments, soluble FGF receptor fusion proteins, containing
the ligand-binding domain of each receptor fused to the
carboxyl terminal Fc region of human IgG1 (R&D Systems,
Minneapolis, MN, U.S.A.) were added to the assay media
in the amounts indicated in the figure legends. After 72 h at
37°C, a 20-l sample of Alamar BlueTM (AccuMed Inter-
national, Westlake, OH, U.S.A.) was added to each well
and the cells were returned to the incubator. After 20 h, the
fluorescence was monitored at excitation and emission
wavelengths of 544 nm and 590 nm, respectively. The
background signal intensity (200–400 fluorescent units)
from wells without growth factor was subtracted from the
values obtained in its presence.ISOLATION AND CULTURE OF CHONDROCYTES FROM HUMAN AND
PORCINE ARTICULAR CARTILAGE
Adult human talus joints were obtained from the North-
west Tissue Center (Seattle, WA, U.S.A.). Full thickness
articular cartilage slices were aseptically collected and
placed in Dulbecco’s Modified Eagles Medium (DMEM,
Hyclone Laboratories, Logan, UT, U.S.A.). Chondrocytes
were isolated using a modification of the method reported
by Kim and Conrad7. The slices were incubated with
0.5-mg trypsin/ml in DMEM for 30 min at 37°C. The super-
natant was removed and the slices further incubated at
37°C for 18 h in DMEM containing 10% FBS (Hyclone
Laboratories, Logan, UT, U.S.A.), 1-mg collagenase-P/ml
(Boehringer-Mannheim, Indianapolis, IN, U.S.A.), 1.0-mg
porcine hyaluronidase/ml (Sigma Chemical Company,
St Louis, MO, U.S.A.). The supernatant was passed
through a 70 m cell strainer to remove cell debris and
undigested cartilage. The isolated chondrocytes were
counted with the aid of a Neubauer haemocytometer and
were plated in DMEM containing 10% FBS in 24-well tissue
culture plates at a high density of 2.6×105 cells per well
and returned to the incubator. After 24 h, the cell layerswere rinsed, and cultured in serum-free DMEM without
additional supplements. A week later, fresh serum-free
DMEM was added with or without 100 ng FGF18 protein/
ml. The appropriate media were replaced twice per week
and cell numbers were determined weekly. At various
times, cells were extracted with 0.4 M NaCl, 50 mM Tris,
pH 7.4 containing 0.5 M EDTA and 0.1% Triton (50 l/well).
30 l aliquots were acidified with 70 l 0.5 M acetic acid,
and treated with 10-g pepsin/ml at 4°C for 6 h. The
reaction was stopped with pepstastin (1:20 w/w) and the
samples dried. All samples were brought up in 30 l
Laemmli sample buffer and the proteins in 15 l aliquots
were separated by SDS-PAGE. Type II collagen was
detected by chemiluminisence (NEN Life Sciences
Products, Boston, MA, U.S.A.), after transblotting onto
PVDF using the antibody 1C10 (1.0 g/ml) that specifically
detects an epitope in denatured 1(II) CB9, 7. It detects
type II collagen chains on Western blots (D. Eyre, unpub-
lished data). Pepsin treated human fetal type II collagen
was used as a control.
Porcine articular cartilage slices were obtained from
3–5-month-old pigs and digested at 37°C overnight with
1 mg/ml collagenase (Worthington Biochemicals, NJ) in
RPMI medium (Life Technologies). After passing through a
100 m Falcon cell strainer , the cells were washed, and
plated directly into 48-well plates to monitor either cell
growth (4000 cells per well) or proteoglycan synthesis
(30,000 cells per well). The assay medium was DMEM/F12
supplemented with 2 M L-glutamine, 1 mM Na pyruvate,
20 g/ml bovine transferrin, 3 ng/ml Na selenite, 10 g/ml
fetuin, 25 mM Hepes (pH 7.2), and 100 g/ml L-ascorbic
acid 2- phosphate. FGF18 was added 1–2 days after
plating and fresh factor was added 3 days later. The
experiments were terminated at 6–7 days. Cell proliferation
was measured using Alamar Blue as described above.
Proteoglycan synthesis was measured by labeling the cells
during the last 16 h of culture with 5-Ci/ml [35S]-Sulfur
(1325 Ci/mmole, NEN, Boston, MA) in the presence of
80-g/ml B-aminopropionitrile. Glycosaminoglycans were
precipitated with 1% cetylpyridinium chloride using 1 g/ml
chondroitin sulfate as carrier. Pellets were washed three
times with PBS, solubilized with 0.5 ml of methanol, and
counted as described above.ADENOVIRUS-MEDIATED GENE TRANSFER
The cDNA for Fgf18 was cloned into pACCMV (Microbix
Biosystems, Inc., Ontario, Canada) and co-transfected into
293 cells (ATCC No. CRL-1573) with the plasmid pJM178
containing an E1 deleted adenovirus genome. Recombina-
tion between the two plasmids results in viral plaque
formation. The recombinant adenovirus was plaque puri-
fied, amplified, and purified as previously described9. Virus
particle number was determined by spectrophotometry and
infectious particle number was determined by a plaque
forming unit assay. All adenovirus preparations were dem-
onstrated to be free of wild-type virus. The virus preps were
diluted to a working concentration of 5×1010 pfu/ml in 5%
glycerol and a final concentration of 1 mg/ml trypan blue.
Prior to injection of adenovirus, female BALB/C nu/nu mice
(JAX, Bar Harbor, ME, U.S.A.), 7–9 weeks of age, were
anesthetized using a single dose of ketamine (40 mg/
kg)+xylazine (8 mg/kg). Each pinna was held loosely
across the center with forceps and the adenovirus was
delivered using a 30 ga needle that was inserted sub-
dermally 2–3 mm from the tip of the pinna. ApproximatelyFgf18-mediated increase in chondrocyte proliferation,
type-II collagen synthesis, and extracellular matrix produc-
tion. Similar effects were seen in subsequent studies of
primary cultures of porcine and adult human articular
chondrocytes incubated with highly-purified FGF18 protein.
That Fgf18 might play a role in the biology of normal
cartilage was suggested by our observations that Fgf18
mRNA and mRNA for two of its receptors, Fgfr 3-(IIIc) and
Fgfr 2-(IIIc), were localized within chondrocytes of human
articular cartilage.
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then delivered slowly through the needle, creating a small
pocket under the skin. Six mice were injected in the left
pinna with adeno-Fgf18 and in the right pinna with adeno-
null. After recovery from anesthesia, mice were returned to
their cages and were monitored daily with minimal manipu-
lation of the pinnae. Two mice were sacrificed 5 days, 11
days, and 17 days following injection of the virus. Pinnae
were removed and fixed immediately in 10% neutral buff-
ered formalin and transferred to 70% ethanol 24 h later.
Each pinna was routinely processed, embedded in paraffin,
sectioned at 5 m and stained with hematoxalin/eosin or
toluidine blue. Elastin was stained in some sections by the
method of Verhoeff10.DETECTION OF MRNA BY IN SITU HYBRIDIZATION
In situ hybridization probes were designed against the
human Fgf18, human Fgfr 2-(IIIc), human Fgfr 3-(IIIc),
human Fgfr 4, mouse Fgf18 and rat Fgfr 4 sequences. A
full-length cDNA plasmid, containing 0.6 kb of the coding
region, 0.4 kb of the 5′UTR and 0.3 kb of the 3′UTR, was
used as a template to generate the human Fgf18 ribo-
nucleotide probe. For the human Fgfr 2-(IIIc), human Fgfr
3-(IIIc), and human Fgfr 4, PCR amplified products were
used as templates for probe synthesis. The working primer
sequences for human Fgfr 2-(IIIc), human Fgfr 3-(IIIc) and
human Fgfr 4 were GGCTGCCCTACCTCAAG (upper) and
AGCCGAAACTGTTACCTGTC (lower); TGACGCACAGC
CCCACATCCAGT (upper) and GCAGGCGGCAGAGCGT
CACAG (lower); and TGACACAGTGCTCGACCTTGATAG
(upper) and ACGCCATTTGCTCCTGTTTTC (lower) re-
spectively. A sequence of the T7 RNA polymerase promoter
was linked to all lower (antisense) primers. For the mouse
Fgf18 probe, a plasmid containing 0.3 kb of the coding
region and 0.7 kb of the 3′UTR was used as the template
for riboprobe synthesis. A plasmid containing 0.4 kb of the
3′UTR and the entire coding region was used to generate
the rat Fgfr 4 probe. Probes for human collagen type II and
type I were used as positive and negative controls, respect-
ively in studies of human talus cartilage. The type II
collagen probe is 0.4 kb located in the 3′UTR of human
alpha1 (II) and the collagen type I probe covered exons 1-9
of human alpha1 (I). Antisense probes were synthesized
using RNA polymerases following procedures described in
the Riboprobe in vitro Transcription System (Promega
Corp., Madison, WI, U.S.A.). The DIG RNA Labeling Mix
was used for the digoxigenin labeled ribonucleotide probes
(Boehringer Mannheim Corp. Indianapolis, IN, U.S.A.).
Purification with a Centriflex Gel Filtration Cartridge (Edge
BioSystems, Gaithersburg, MD, U.S.A.) was performed to
eliminate non-incorporated nucleotides. The probe was
evaluated by direct immunological detection using anti-
bodies against DIG to determine labeling efficiency, and
further analysed by electrophoresis to confirm the transcript
size.
Human talus joint articular cartilage slices and mouse
pinnal tissues were rinsed with PBS and fixed in 10%
buffered formalin, embedded in paraffin and sectioned at
5 m. After removal of the paraffin, tissues were digested
with 50 g Proteinase K/ml for 5 min at 37°C, briefly fixed
again in 4% paraformaldehyde and acetylated. Human
Fgf18, human Fgfr 2-(IIIc), human Fgfr 3-(IIIc) and human
Fgfr 4 probes were used on all human talus joint tissue
samples. For mouse pinnal tissues, mouse Fgf18, human
Fgfr 2-(IIIc) and human Fgfr 3-(IIIc), and rat Fgfr 4 probeswere utilized. Homologies in the probe sequences between
the mouse and human Fgfrs is 92–94%, and between
mouse and rat Fgfr 4 is 87%. Stringent reaction conditions
were selected to ensure specific annealing of the probes.
Hybridization was performed with DIG labeled probes at
1–5 pmol/ml in solution containing 50% formamide and
2×SSC for 12 to 16 h at 55–60°C. The slides were subse-
quently washed in 2×SSC and 0.1×SSC at 50–55°C. The
signals were amplified with two to three rounds of tyramide
signal amplification (TSA in situ indirect kit, NEN Life
Science Products, Boston, MA, U.S.A.) and visualized with
Vector Red substrate kit (Vector Laboratories, Burlingame,
CA, U.S.A.). Slides of human articular cartilage were
counterstained with hematoxylin and imaged under bright
field. For mouse pinnal tissue sections, DAPI was used
as the counterstain and the images were taken under
fluorescence.IMMUNOCYTOCHEMISTRY
Fixed pinnal tissues were processed in a Tissue-Tek VIP
2000, embedded in paraplast X-tra, and sectioned at 5 m.
Pinnal sections were deparaffinized, hydrated with water,
and subjected to epitope retrieval with pepsin (Neo-
Markers, Fremont, CA, U.S.A.) for 20 min at room tempera-
ture. The localization of type II collagen, FGF18, and FGFR
1–4 was determined using an immunoperoxidase (IP)
immuno-histochemical protocol with avidin-biotin-complex
detection system (Vantana Biotek Systems, Tucson, AZ,
U.S.A.). Sections were preblocked with 5% normal goat
serum (NGS) (Vector Laboratories, Burlingame, CA,
U.S.A.) and were incubated with a primary antibody against
type II collagen (mouse anti-collagen type II Ab-2, clone
2B1.5, 200 g/ml, 1:100 dilution, NeoMarkers) or a primary
rabbit anti-human FGFR antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, U.S.A.): FGF R1, Flg (C-15): sc-121;
FGF R2, Bek (C-17): sc-122; FGF R3, (C-15):sc123; or
FGF R4 (C-16): sc-124 each tested at working dilutions of
1:200, 1:400, and 1:800. The FGFR 1–3 antibodies are
directed against a common domain in the carboxy terminal
region and thus do not distinguish the ‘b’ and ‘c’ receptor
splice variants. Detection of proliferating cell nuclear anti-
gen (PCNA) was by direct immunohistochemical staining
with a biotinylated mouse anti-PCNA antibody (0.2 mg/ml,
1:100 dilution, Zymed, South San Franscisco, CA, U.S.A.).
Biotinylated goat antimouse IgG (1.5 mg/ml, 1:200 dilution,
Vector Laboratories) plus 2% NGS in PBS was used as the
secondary-linking antibody for detection of type II collagen
and FGF18. For FGFR staining, a biotinylated goat anti-
rabbit IgG (1:200 dilution in PBS containing 2% NGS,
Vector Laboratories) was used. Antibody specificity was
confirmed using the appropriate non-immune primary sera
and known positive tissue sections. Immunoperoxidase
labeling was performed with a Vantana peroxidase DAB kit
(Vantana Biotek Systems) using diaminobenzidine precipi-
tation. Tissues were counterstained with methyl green.
Slides were observed using a Nikon microscope and
images were recorded with a CoolSnap (RS Photometrics)
digital camera system.EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN FGF18
Fgf18 was expressed in E. coli using the MBP (maltose
binding protein) fusion system (New England Biolabs). In
this system, the mature Fgf18 cDNA was attached to the 3′
Osteoarthritis and Cartilage Vol. 10, No. 4 311Fig. 1. (a–h).
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Fig. 2. Effect of FGF18 on DNA and proteoglycan synthesis in
primary cultures of porcine articular chondrocytes. Primary cul-
tures of porcine articular chondrocytes were incubated in increas-
ing amounts of FGF18 for 5–6 days. Cell proliferation (open
symbols) was monitored by AlamarBlue and proteoglycan syn-
thesis (closed symbols) was measured by [35S] sulfate incorpor-
ation as described under Materials and methods.Fig. 1. (i–l)
Fig. 1. Histology of mouse pinnae transduced with adenovirus expressing Fgf18. Pinnae were harvested on day 5 after infection with either
a control adenovirus (left panels) or adenovirus expressing Fgf18 (right panels). Panels a,b: hematoxylin and eosin [10×, boxed outlines
magnified areas in panels (c) and (d)]; panels (c), (d): hematoxylin and eosin, 20×, panel (c) arrow, lipochondrocyte, panel (c) arrowhead,
perichondrial cells; panel (d) arrows, newly formed ‘chondrocyte-like’ cells; panels (e), (f): immunoperoxidase, type II collagen, 10×; panels
(g), (h): immunoperoxidase, proliferating cell nuclear antigen, 10×, panel (h) arrow demonstrates PCNA positive chondrocytes; panels (i), (j):
toluidine blue, 10×; panels (k), (l): Verhoeff’s stain for elastin, 10×, arrows illustrate elastin deposition.end of the malE gene to form an MBP-FGF18 fusion
protein. The construct was built as in-frame fusions with
MBP in accordance with the Multiple Cloning Site (MCS)
of the pMAL-c2 vector (New England Biolabs) according
to the manufacturer’s instructions. E. coli fermentation
medium containing MBP-FGF18 was solubilized in a cell
disrupter, using a lysis buffer containing 50 mM phosphate,
pH 7.2, 0.4 M NaCl, 10 mM EDTA, 0.4 mM phenylmethyl-
sulfonylfluoride, and 1 M each of leupeptin and pepstatin.
The lysate was centrifuged and the resulting supernatant
was batch loaded on AF-Heparin-650M resin (TosoHaas,
Montgomeryville, PA, U.S.A.) in roller bottles overnight at
4°C. The resin was washed and then incubated in roller
bottles at room temperature for 3 h in a modified lysis buffer
containing 15 mg/l thrombin without EDTA or protease
inhibitors. The resin was then washed with 50 mM phos-
phate, pH 7.2, 0.4 M NaCl, 10 mM EDTA and the cleaved
product FGF18 was step-eluted with wash buffer containing
1.75 M NaCl. The pooled AF-Heparin fractions were
diluted to ∼46 mS/cm conductivity using 50 mM sodium
phosphate, pH 7.8, and passed over a bed of Benza-
midine Sepharose (Amersham Pharmacia Biotech, Inc.,
Piscataway, NJ, U.S.A.) to remove residual thrombin. The
unbound fractions were collected together and were diluted
five-fold with 50 mM phosphate, pH 7.5, and loaded on
Osteoarthritis and Cartilage Vol. 10, No. 4 313a Poros 20 HS cation exchange column (Perceptive
Biosystems, Framingham, MA, U.S.A.) before eluting with
a gradient (0–2.0 M) of NaCl. Fractions containing FGF18
were collected together and disulfide formation in FGF18
was then carried to completion by oxidation with CuSO4 at
a final concentration of 0.5 mM. Finally, aggregates and
residual impurities were removed with a Sephacryl S-100
size exclusion column (Amersham Pharmacia Biotech,
Inc.) operated with formulation buffer containing 50 mM Na
phosphate, pH 7.2, 1 M NaCl, and 10 mM EDTA. The
purified FGF18 showed a single species at about 20 kDa
on reducing SDS-PAGE analysis. The homogeneity of the
FGF18 preparation was confirmed by N-terminal sequenc-
ing and mass spectrometry analyses. The FGF18 was
dialysed into 1.0 M NaCl, 0.01 M EDTA, 0.05 M Na-
phosphate, and pH 7.2 and was stored at −80°C until use.Fig. 3. Effect of FGF18 on cell proliferation and synthesis of type II collagen in primary cultures of adult human articular chondrocytes.
Chondrocytes from the human talus joint were isolated from cartilage slices and cultured in the absence of FGF18 for one week as described
under Methods. Vehicle alone or vehicle containing FGF18 (100 ng/ml final concentration) was added (arrow) and the cells were cultured for
the indicated time as described under Methods. Cell proliferation [panel (A)] was measured weekly by direct cell counts. Type II collagen
deposited in the extracellular matrix (panel B) was assessed by Western blotting as described under Methods. The antibody 1C10 detected
the 1(II) collagen chains of type II collagen. **The faint band migrating below the 1(II) collagen chain is a pepsin over-cleavage product
of type II collagen33,34. Wk=weeks.Results
The angiogenic potential of Fgf18 was assessed by
adenovirus-mediated transfer of Fgf18 into the pinnae ofnude mice. While no apparent angiogenic response was
observed, pinnae that received adeno-Fgf18 became vis-
ibly thicker and developed a reddish-brown coloration.
Tissue thickening was observed within 4 days of inoculation
and remained localized around the injection site for up to 17
days. Pinnae that received adeno-null contained a narrow
band of chondrocytes within the central zone of elastic
cartilage [Fig. 1(a), (c)]. The vacuolated cells in the center
of this region [Fig. 1(c), arrow] are ‘lipochondrocytes’
whose cytoplasmic spaces are swollen with a large cyto-
plasmic lipid droplet11. Few chondrocytes were observed
outside of this region, the central zone lipochondrocytes
were bordered by flattened perichondrial cells without obvi-
ous lipid inclusions or chondrocyte morphologies [Fig. 1(c),
arrowhead]. Infection with adeno-Fgf18 greatly expanded
the number of basophilic ‘chondrocyte-like’ cells observed
around the site of inoculation [Fig. 1(b), (d)] and extending
outwards from the auricular cartilage zone into the skeletal
muscle and subcutis. These cells were strongly stained
with an antibody to PCNA as were hair follicles and
epithelium [Fig. 1(g), (h)]. Chondrocytes were identified by
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Fig. 4. Effects of FGF18 on the proliferation of BaF3 cells expressing FGF receptor splice variants. BaF3 cells expressing the ‘b’ and ‘c’ splice
variants of FGF receptors 1-3 were incubated in the presence and absence of the indicated concentration of FGF-1, FGF-2 or FGF18 and
cell proliferation was measured as described under Methods. The following BaF3 cell lines were used: panel (A), FGF R1-(IIIb) cells; panel
(B), FGF R1-(IIIc) cells; panel (C), FGF R2-(IIIb) cells; panel (D), FGF R2-(IIIc) cells; panel (E), FGF R3-(IIIb) cells; and panel F, FGF
R3-(IIIc) cells. Each point represents the average of duplicate wells of cells from two separate experiments.staining of adjacent sections with a type II collagen anti-
body. Relative to pinnae infected with adeno-null [Fig. 1(e)],
type II collagen immunoreactivity was greatly increased by
infection with adeno-Fgf18 [Fig. 1(f)]. Enhanced staining for
type II collagen was evident by day 5 and was maintained
near this level for up to 17 days. No staining was detected
with a mouse isotype-specific control antibody (data not
shown). The matrix surrounding the chondrocytes also
showed increased staining with toluidine blue [Fig. 1(i), (j)].
In contrast, adeno-Fgf18 had little or no effect on elastin
(19) deposition in mouse pinnal tissue [Fig. 1(k), (l)]. Thus,
adenovirus-mediated transfer of Fgf18 into mouse pinnae
increased the proliferation of pinnal chondrocytes and
greatly increased the production of type II collagen and
extracellular matrix by these cells.
In short-term (≤1-week) cultures of primary porcine
chondrocytes, addition of FGF18 to the cell media pro-
duced an increase in cell proliferation that was paralleled
by an increase in [35S]-sulfate incorporation into proteogly-
cans (Fig. 2). The proliferation of primary adult human
articular chondrocytes in long-term (≤5 weeks) culture was
also increased by the addition of 100 ng FGF18/ml [Fig.
3(A)]. In these experiments, chondrocytes were cultured for
1 week in the absence of FGF18 and then in its presence
for up to 4 weeks. Increased chondrocyte cell numbers
were observed within 1 week after the addition of FGF18.
Chondrocyte proliferation was maintained for three weeks
of culture in the presence of FGF18 and then declined [Fig.
3(A)]. The reason for the reduction in chondrocyte cellnumber after 5 weeks of culture is not clear but could be
due to a loss of sensitivity to FGF18 or to a more general-
ized reduction in proliferative activity after long-term cul-
ture. Western blot analysis of collagen deposited in the
extracellular matrix showed an apparent increase in type II
collagen accumulation within one week after the addition of
FGF18 [Fig. 3(B)]. Type II collagen accumulated in the
matrix throughout the 5-week duration of the study [Fig.
3(B)]. Similar observations were made with adult human
talus chondrocytes maintained as high-density micromass
cultures: chondrocyte cell numbers, staining of chondro-
cyte nuclei with antibodies to PCNA, type II collagen
accumulation, and staining of proteoglycans with
safranin-O were increased by incubation with media con-
taining 100 ng FGF18/ml for 2 weeks (data not shown).
Taken together, these data demonstrate that FGF18 stimu-
lated the proliferation of porcine and adult human articular
chondrocytes in primary cell culture. In addition, these data
show that the differentiation state of the chondrocytes, as
determined by type II collagen and proteoglycan produc-
tion, was maintained by FGF18 under these conditions.
BaF3 cells have been used extensively to study the
activities of receptor tyrosine kinases, including receptors
of the FGF family12. To evaluate the receptor selectivity of
FGF18 in this system, BaF3 cells expressing the major
splice variants of the Fgfr genes were incubated with
increasing amounts of FGF18. In a separate series of wells,
either FGF1 or FGF2 was added in place of FGF18 as a
positive control. Addition of FGF18 had little or no effect on
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Fig. 5. Competition for FGF18-mediated proliferation of BaF3 cells
by soluble FGF receptor-Fc fusion proteins. BaF3 cells expressing
FGF R3-(IIIc) were incubated in the presence and absence of
0.8 ng FGF18/ml and the indicated fold-excess (based on protein
mass) of the various FGF R-Fc fusion proteins. Cell proliferation
was measured as described under Methods. The 100% value of
cell proliferation measured in the absence of FGFR-Fc was about
1000 Alamar blue units. Each point represents the average of
duplicate dishes of cells from two separate experiments. FGFR1c-
Fc, ——; FGFR2b-Fc, ——; FGFR2c-Fc, ——; FGFR3c-Fc,
——; FGFR4-Fc, ——.Fig. 6. Detection of Fgf18, Fgfr 2-(IIIc), Fgfr 3-(IIIc), and Fgfr 4 mRNAs in murine pinna by in situ hybridization. The hybridization signals were
visualized with Vector Red substrate and imaged with a FITC/Texas Red filter (left panels). Tissue intrinsic fluorescence (green) was
imaged with a Blue filter to provide tissue orientation (middle panels). Due to broad excitation and emission wavelength of the Vector Red
dye, a fraction of the Vector Red staining can also be visualized with this filter. Nucleic counter staining was achieved by DAPI and imaged
with a DAPI filter (right panels). Panels (A)–(D) are images of adeno-Fgf18 infected pinnae. Panel (E) is an image of adeno-null infected
pinna. All images are orientated with central zone lipochondrocytes in the upper left corner. (A): Fgfr-2(IIIc); (B): Fgfr-(3IIIc); (C): Fgfr4;
(D) & (E): Fgf18.the proliferation of cells expressing the Fgfr 1-(IIIb), Fgfr
1-(IIIc), Fgfr 2-(IIIb), or Fgfr 3-(IIIb) genes [Fig. 4(A)–(C),
(E)]. In parallel cultures, addition of either FGF2 [Fig.
4(A),(B)] or FGF1 [Fig. 4(C),(E)] increased cell proliferation,
as reported previously12. BaF3 cells expressing either Fgfr
2-(IIIc) [Fig. 4(D)] or Fgfr 3-(IIIc) [Fig. 4(F)] responded to
FGF18 with a dose-dependent increase in cell proliferation.
The apparent EC50s for these effects in the Fgfr 3-(IIIc) and
Fgfr 2-(IIIc) expressing cells were approximately 2 and
12 ng FGF18/ml, respectively. Heparin was absolutely
required for the induction of cell proliferation, as under
identical conditions in the absence of heparin, FGF18 was
without effect (data not shown). A similar pattern of receptor
selectivity in the BaF3 cells was observed with FGF18
produced in Chinese hamster ovary cells (data not shown).
To further assess the relative receptor selectivity of
FGF18, a series of soluble human FGF receptor-Fc fusion
proteins were used in competition studies with BaF3 cells
expressing Fgfr 3-(IIIc). The fusion proteins used consisted
of the extracellular domain of each FGFR fused to the
carboxy-terminal Fc region of human IgG1. Addition of
either FGFR 3-(IIIc)-Fc or FGFR 4-Fc produced a dose-
dependent inhibition of FGF18-mediated cell proliferation(Fig. 5). Competition was also observed with FGFR 2-(IIIc)-
Fc, however, the apparent IC50 was about 100-fold higher
than that found with FGFR 3-(IIIc)-Fc or FGFR 4-Fc (Fig.
5). Over this concentration range, no competition was
observed with FGFR 1-(IIIc)-Fc or with FGFR 2-(IIIb)-Fc
(Fig. 5). Taken together, these data demonstrate that
FGF18, in the presence of heparin, can bind and activate
FGFR 4, FGFR 3-(IIIc) and FGFR 2-(IIIc). FGF18
appeared, moreover, to bind neither the FGFR ‘b’ splice
variants nor did it bind and activate FGFR 1 under these
conditions. These data are consistent with FGF18 receptor
specificity reported recently by Xu et al.13
To assess the expression of Fgf18 and Fgfrs within
chondrocytes of murine pinnae, paraffin embedded pinnal
tissue from adeno-Fgf18 treated mice was subjected to in
situ hybridization with specific riboprobes for Fgf18 and its
receptors. For clarity, images of the perichondrial zone of
proliferating chondrocytes adjacent to the central zone
lipochondrocytes are shown. A portion of the central zone is
shown in the upper left hand corner of each image. Expres-
sions of Fgf18, Fgfr 2-(IIIc), Fgfr 3-(IIIc), and Fgfr 4 were
detected within the expanded chondrocyte zone in the
pinnae [Fig. 6(A),(D), left panels]. Little or no expression of
these genes was detected, in contrast, within the mature
lipochondrocytes [Fig. 6(A),(D), upper left corner of each
image] of the pinnal tissue. Similarly, little or no Fgf18
mRNA was detected in resting pinnal chondrocytes in
tissue infected with adeno-null [Fig. 6(E), left panel]. Rela-
tive to pinnae treated with adeno-null [Fig. 6(E)], an
increased number of cells within this zone was clearly
evident from images of tissue autofluorescence [Fig. 6(A)–
(E), middle panels] or from nuclear staining with DAPI (Fig.
6, right panels). Thus, the chondrocytes of murine pinnae
transduced with adeno-Fgf18 express Fgf18, Fgfr 4 and the
(IIIc) splice variants of Fgfr 2 and Fgfr 3.
To evaluate expression of Fgfr in more detail, pinnae
infected with adeno-null or adeno-Fgf18 were immuno-
stained with antibodies directed against the carboxytermi-
nal domains of FGFRs 1–4. A high level of background
staining was observed with the antibodies directed against
FGFR 1, 3, and 4 in virtually all cell types within the tissue.
Antibodies to FGFR 2, in contrast, displayed minimal back-
ground and intensely stained the cells of the expanded
chondrocyte population in pinnae treated with adeno-Fgf18
[Fig. 7(a)]. Staining was specific for FGFR 2 as a non-
immune isotype control antibody failed to stain the tissue
[Fig. 7(b)]. On higher magnification, most of the staining
with the FGFR 2 antibody was observed within nuclei
of the proliferating chondrocytes [Fig. 7(c),(d)]. In tissue
treated with adeno-null, a few chondrocyte nuclei in the
perichondrial zone were stained with the FGFR 2 antibody
[Fig. 7(c)]. With adeno-Fgf18, the number of anti-FGFR 2
stained chondrocyte nuclei was greatly increased [Fig.
7(d)]. The highest level of expression of FGFR 2 within
pinnal chondrocytes was seen on day 5 through day 11
post-infection. Anti-FGFR 2 staining decreased in these
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antibody was also observed within blood vessels and
epidermis of pinna treated with either adeno-null or adeno-
Fgf18 (data not shown). As described above, FGF18 can
bind and activate the ‘IIIc’ but not the ‘IIIb’ form of FGFR 2
suggesting that FGFR 2-(IIIc) may mediate, at least in part,
chondrocyte proliferation in response to infection of pinnae
with adeno-Fgf18.
The data described above suggested that FGF18 could
act as a trophic factor for auricular and articular chondro-
cytes. To evaluate whether the Fgf18 is expressed in
normal human articular cartilage, cartilage slices from the
adult human talus were fixed and processed for mRNA
localization by in situ hybridization. Fgf18 mRNA was
specifically localized within the cytoplasm of the chondro-
cytes in these tissues [Fig. 8(a)]. On consecutive sections,
these cells also stained with a riboprobe specific for type II
collagen [Fig. 8(d)] but not with a probe for type I collagen
[Fig. 8(e)]. Using splice variant specific riboprobes for two
of the high affinity FGF18 receptors, Fgfr 3-(IIIc) [Fig. 8(b)]
and Fgfr 2-(IIIc) [Fig. 8(c)] mRNAs were also consistently
detected within chondrocytes in these tissues. In contrast,
little or no consistent expression of Fgfr 4 was detected
(data not shown). Similar results were obtained using
RT-PCR to examine expression of these genes in fresh
samples of adult human articular cartilage and in primary
chondrocytes isolated and cultured from these tissues(data not shown). These data demonstrate that Fgf18, Fgfr
2-(IIIc) and Fgfr 3-(IIIc) are expressed in chondrocytes of
normal human articular cartilage.Fig. 7. Expression of FGF R2 within chondrocytes of murine pinna transduced with adeno-Fgf18. Mouse pinna were harvested on day 5 after
infection with either adeno-null (panel c) or adeno-Fgf18 [panels (a), (b), (d)]. Immunoperoxidase staining using antibodies to FGF R2 [panels
(a), (c), (d)] or a non-immune isotype control antibody [panel (b)]. Sections were imaged at either 20× [panels (a), (b)] or 40× [panels (c),
(d)]. Large arrows: chondrocytes expressing FGF R2; small arrow: lipochondrocyte.Discussion
The results reported here demonstrate that FGF18 has
significant anabolic effects on chondrocytes in vitro and in
vivo. The effects included both increased deposition of
matrix proteoglycans and type II collagen and stimulated
cell proliferation. The cellular source of the proliferating
chondrocytes in adeno-Fgf18 treated pinnae is not entirely
clear. The cartilage plate of pinnal tissue consists of a
perichondrium, a boundary zone and a central zone11. The
perichondrial cells are flattened and are surrounded by and
contain abundant type II collagen, while boundary zone
cells have an abundant cytoplasm rich in organelles and a
matrix containing type II collagen, proteoglycan and elas-
tin11. The central zone contains what appear to be fully
differentiated chondrocytes swollen by cytoplasmic lipid
inclusion bodies and abundant pericellular elastin fibers11.
Boundary or perichondrial cells are thought to respond to
cartilage plate injury11, and so are candidate progenitors.
This region expands in the adeno-Fgf18 treated pinnae;
with numerous PCNA positive cells and cells staining for
proteoglycan and type II collagen. Alternatively, the
318 J. L. Ellsworth et al.: Fibroblast growth factor-18Fig. 8. Localization of Fgf18, Fgfr 2-(IIIc), and Fgfr 3-(IIIc) mRNAs in human articular cartilage by in situ hybridization. Articular cartilage from
the human talus joint was isolated and prepared for in situ hybridization with specific ribonucleotide probes for either human Fgf18 [panel (a)],
Fgfr 3-(IIIc) [panel (b)], or Fgfr 2-(IIIc) [panel (c)] as described under Methods. Alpha1(II) [panel (d)] and alpha1(I) [panel (e)] collagen probes
were used as positive and negative controls, respectively. Detection of a specific mRNA is indicated by red staining. Similar results were
obtained with articular cartilage from three separate individuals. Each bar represents 20 nm.chondrocytes may have formed from mesenchymal stem
cells in this region. It is notable that in punch wounds in the
rabbit ear; mesenchymal cells appeared to grow out of the
dermis and perichondrium to form a chondrocyte cell con-
densation during the later stages of the repair response14.Little or no effect of adeno-Fgf18 was seen on the
lipochondrocyte cell population or the matrix of the central
zone in the mouse pinnae. This is consistent with the lack
of expression of Fgfrs in these cells observed in the present
study and their lack of proliferative activity by post-natal day
Osteoarthritis and Cartilage Vol. 10, No. 4 31912 of development11. It is possible that the newly formed
chondrocytes would have differentiated into mature lipo-
chondrocytes over a longer observation period than 17
days. Pinnal perichondrial cells and chondrocytes arise
from the pre-cartilaginous mass in the developing ear15.
The effects of FGF18 on auricular cartilage thus appear to
be specific to inducing a population of chondrocytes that
synthesize and secrete type II collagen and proteoglycans,
and not the characteristic resident elastic cartilage cells.
Another member of the FGF family, FGF2, appears to be
a key regulator of bone growth and development. Disrup-
tion of Fgf2 in mice results in decreased osteoblast repli-
cation and bone formation16, while overexpression of Fgf2
in transgenic mice produced chondrodysplasia and major
defects in the long bones and bones of the skull17,18. It was
proposed17,18 that the latter activity was mediated by the
inhibitory actions of FGF2 on chondrocyte terminal differ-
entiation. This hypothesis is supported by other studies that
have demonstrated a negative role of FGF2 on the growth
and differentiation of growth plate chondrocytes18,19. How-
ever, in vitro studies with FGF2 and chondrocytes from a
variety of sources have yielded inconsistent results both
with regards to growth and production of extracellular
matrix20–24. In this study, we show that auricular and
articular chondrocytes appear to respond to FGF18 simi-
larly. In addition to the trophic effects of adeno-Fgf18 on
auricular chondrocytes in vivo, we found that FGF18 stimu-
lated the proliferation of porcine articular chondrocytes in
vitro, and that this proliferation was accompanied by a
parallel increase in proteoglycan synthesis. With adult
human articular chondrocytes, moreover, the synthesis and
accumulation of type II collagen increased after one week
of incubation with FGF18. The differentiated phenotype of
the proliferating chondrocytes, therefore, appears to be
maintained in the presence of FGF18. Whether FGF18 is
required for the formation or maintenance of cartilages
in vivo must await the production and study of models of
FGF18 gene disruption.
Transduction of signals from extracellular FGF is medi-
ated by members of the FGF receptor gene family, FGFR
1–425. In combination with a sulfated proteoglycan, FGFs
bind and activate receptor tyrosine kinase activity, a pro-
cess believed to be regulated by receptor dimerization25.
Using FGF receptor-bearing BaF3 cells, highly purified
FGFs, and soluble FGFR-Fc fusion proteins, FGF18 was
shown in the present report to bind and activate FGFR 4
and the IIIc splice variants of FGFR 2 and FGFR 3.
Consistent with studies with other FGFs25, receptor acti-
vation by FGF18 was entirely dependent on exogenous
heparin. Although FGF18 appears to be more selective in
receptor specificity than either FGF-1 or FGF-2 in the BaF3
cell system12, how these data translate to receptor selec-
tivity in intact tissues is not clear. Chang et al.26 have
recently reported that tissue-specific heparan sulfate mol-
ecules can differentially affect FGF and FGF receptor
binding in situ.
It is not yet understood which FGF receptor(s) mediates
the effect of FGF18 on chondrocytes. In the mouse pinnae
transduced with adeno-Fgf18, Fgfr 2-(IIIc), Fgfr 3-(IIIc), and
Fgfr 4 mRNAs were detected within proliferating chondro-
cytes in the expanded perichondrial zone. In addition, the
nuclei of the proliferating chondrocytes were intensely
stained with antibodies to FGFR 2. The nuclear localization
is consistent with previous observations that other FGFRs
traffic from the plasma membrane to the nucleus in
response to FGF127. Hence the nuclear localization of
FGFR 2 in the auricular chondrocytes suggests that thisreceptor is involved in the proliferation of these cells in
response to FGF18. Unfortunately, a high level of back-
ground staining prevented us from determining whether
other FGFR proteins can also be localized to the nuclei of
auricular chondrocytes. Analysis of adult human articular
cartilage by in situ hybridization demonstrated the pres-
ence of Fgfr 3-(IIIc) as well as Fgfr 2-(IIIc) mRNAs, thus
opening the possibility that Fgfr 3-(IIIc) may also be
involved in the response to FGF18. In fact, FGFR3 is
known to play a significant role in cartilage biology particu-
larly in the growth plate. Many of the common forms of
dwarfism in humans are caused by activating mutations in
Fgfr 328 and targeted expression of an activated form of
Fgfr 3 to the growth plate of mice produced dwarf mice29.
These data suggest that in the growth plate of long bones,
Fgfr 3 is a negative regulator of chondrocyte proliferation.
However, Iwata et al.30 have reported that signaling
through FGFR 3 can both promote and inhibit chondrocyte
proliferation depending on the stage of development.
Although FGFR 3 signaling appears to be a negative
regulator in long bones, excessive growth of the skull is
seen in human chondrodysplasia caused by activating
mutations in Fgfr 3, implying differing responses to FGFR 3
signaling in the skull and long bones31,32. Thus, the relative
role of FGFR 2 and FGFR 3 in the response of articular
chondrocytes to FGF18 will be important to elucidate.
Lastly, we found that FGF18 mRNA is expressed in
normal human articular chondrocytes, suggesting that
FGF18 plays a physiological role in cartilage biology. Since
articular cartilage is avascular, alymphatic and populated
by a single cell type of relatively immobile chondrocytes, an
autocrine mode of action of FGF18 on cell proliferation and
extracellular matrix production seems most likely. The
anabolic effects of FGF18 on auricular and articular
chondrocytes that we have described here suggest that
FGF18 could potentially be useful in promoting repair of
damaged cartilages. Clearly, much more work is required to
determine its range of activity and mechanisms of actions.Acknowledgments
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